Cannabinoids for Alzheimer's disease: A promising trial, although not yet ready for the prescription pad.

Cury et al. present the first randomized placebo-controlled trial of a low-dose balanced tetrahydrocannabinol-cannabidiol extract targeting cognition in Alzheimer's disease (AD). The study marks a milestone in a field long dominated by anecdotes and low-certainty evidence. While it demonstrated modest cognitive improvement on the Mini-Mental State Examination, the lack of functional and behavioral outcomes raises questions about real-world benefits. Methodological limitations, including a small sample size and limited power, temper interpretation but highlight the need for larger studies. For clinicians, this trial transforms speculation into evidence-based counseling, promoting informed dialogue while cautioning against premature clinical use of unregulated cannabis products in AD care.